Pharnext esPharnext is an advanced, clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the Unit...


Add photos to showcase Pharnext’s culture


Add Pharnext’s values

Insider experiences

Share your experience of working at Pharnext

David Horn Solomon
CEO & Board Member
Adrian Hepner
Chief Medical Officer
François Chamoun
General Counsel
Muriel Cottard
Chief Quality Officer
Peter Collum
Chief Financial Officer and Chief Business Officer
Philippe Rinaudo
Chief Data Science Officer
Rodolphe Hajj
Chief Pharmacology Officer
Serguei Nabirotchkin
Co-Founder, Chief Biology Officer
Susanne Dorn
Chief Regulatory Officer
Viviane Bertrand
Chief Preclinical Drug Development Officer
Xavier Paoli
VP, Chief Commercial Officer

Add your teams to show how people work together at Pharnext

Add jobs to your org chart to show candidates who they’ll work with

Publish company announcements to get more exposure

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.